

**SERODIAGNOSIS OF STRONGYLOIDIASIS:  
IDENTIFICATION OF cDNA CLONES,  
PRODUCTION OF RECOMBINANT ANTIGENS  
AND IMMUNOASSAY DEVELOPMENT**

**NORSYAHIDA BINTI ARIFIN**

**UNIVERSITI SAINS MALAYSIA  
2016**

**SERODIAGNOSIS OF STRONGYLOIDIASIS:  
IDENTIFICATION OF cDNA CLONES, PRODUCTION OF  
RECOMBINANT ANTIGENS AND IMMUNOASSAY DEVELOPMENT**

**by**

**NORSYAHIDA BINTI ARIFIN**

**Thesis submitted in fulfillment of the requirements  
for the degree of  
Doctor of Philosophy**

**March 2016**

## **ACKNOWLEDGEMENTS**

### **All praises is due to Allah, the Most Gracious and the Most Merciful**

First of all, I wish to express my sincere gratitude to my supervisor, Professor Dr. Rahmah Noordin, for her excellent supervision and guidance, and for her invaluable support throughout the research and writing of this thesis. Her passion for and extensive knowledge of research has truly inspired me. I also offer warmest thanks to AP Dr. Zeehaida Mohamad and Dr. Nurulhasanah Othman for their assistance during the research work.

My deepest appreciation goes to all the laboratory staff, especially En. Mohd Hafiznur, Puan Sabariah, Puan Izzati, Puan Dyana and Puan Izan, for their help and co-operation. I really appreciate the excellent team work of the members of Proteomic Lab, in particular Ai Ying, Syazwan, Chang, Kak Anizah, Nad, and the previous students Atefeh, Zohreh, and Akbar, who have seen my struggle and shared my ups and downs. Nor can I forget all the administration staff, especially Cik Fauziah, Puan Nurul, Puan Iman, En. Irwan, En. Azam, and En. Adli for their kind assistance.

This study would not have been possible without the continuous support, patience, and understanding of my husband, Anas. Thanks also go to my parents; they are, in essence, the key to my success. My deepest gratitude also goes to my parents-in-law for their thoughts and prayers and to all my siblings, my in-laws, friends, and the many wonderful people whom I met along the way. I dedicate this thesis to my dear children for them to be inspired one day.

Lastly, I truly appreciate the ASTS fellowship I received from Ministry of Education and Universiti Sains Malaysia (USM). This study was funded by USM Research University grant No: 1001/CIPPM/812078 and ERGS grant from Ministry of Higher Education No: 203/CIPPM/6730048.

## TABLE OF CONTENTS

	Page
Acknowledgements	ii
Table of contents	iii
List of Tables	xii
List of Figures	xiii
List of Abbreviations	xvi
Abstrak	xvii
Abstract	xix

### **CHAPTER ONE - INTRODUCTION**

1.1 Strongyloidiasis: The overview	1
1.2 History of the discovery of <i>S. stercoralis</i>	3
1.3 The organism <i>S. stercoralis</i>	
1.3.1 Taxonomy	4
1.3.2 Morphology	5
1.3.3 Life cycle	8
1.3.3.1 Autoinfection	11
1.4 Epidemiology	11
1.5 Transmission of the infection	17
1.5.1 Horizontal transmission	17
1.5.1.1 Soil transmission	17
1.5.1.2 Oral route of transmission	18
1.5.1.3 Person to person transmission	18
1.5.2 Vertical transmission	19
1.6 Clinical manifestation of strongyloidiasis	20
1.6.1 Acute	20
1.6.2 Chronic	21
1.7 Strongyloidiasis and associated problems	22
1.7.1 Immunosuppressed patients	22
1.7.2 Association with solid organ transplantation	24

1.7.3	Association with HTLV-1 infection	25
1.8	Host immune response	26
1.8.1	Innate immunity	26
1.8.2	Adaptive immunity	27
1.9	Diagnosis of strongyloidiasis	34
1.9.1	Parasitological method	34
1.9.1.1	Direct faecal smear examination	35
1.9.1.2	The concentration method	35
1.9.1.3	Agar plate culture	37
1.9.1.4	Diagnosis method for other clinical specimens	37
1.9.2	Immunological method	39
1.9.2.1	Serology test	39
1.9.2.2	Absolute eosinophil count	41
1.9.3	Faecal antigen detection	42
1.9.4	Molecular biology and other biotechnological methods	43
1.9.4.1	PCR and Real-time PCR	43
1.9.4.2	Recombinant antigens	46
1.9.4.3	LIPS assay	46
1.9.4.4	Luminex	47
1.9.4.5	Rapid test	48
1.10	Treatment	49
1.11	Prevention measures	50
1.12	Statement of problems and rationale of the study	51
1.13	Objectives of the study	53

## **CHAPTER 2: MATERIALS AND METHODS**

2.1	Study design	54
2.2	Materials	59
2.2.1	Preparation of reagents for extraction of <i>S. stercoralis</i> crude antigen	59
2.2.1.1	Phosphate buffered saline (PBS)	59
2.2.1.2	Protease inhibitor	59
2.2.1.3	Lysozyme	59

2.2.1.4	Determination of protein content by RCDC assay	60
2.2.2	Preparation of reagents for ELISA	60
2.2.2.1	0.06M carbonate buffer	60
2.2.2.2	Blocking solution	61
2.2.2.3	PBS – Tween 20 (PBS-T)	61
2.2.2.4	Primary antibody	61
2.2.2.5	Secondary antibody	61
2.2.2.6	Substrate solution	61
2.2.3	Preparation of reagents for serum pre-adsorption	62
2.2.3.1	Luria bertani (LB) broth	62
2.2.3.2	Tetracycline	62
2.2.3.3	LB broth with tetracycline	62
2.2.3.4	Lysis buffer	62
2.2.3.5	Microsphere beads	63
2.2.3.6	Washing solution	63
2.2.3.7	Blocking solution	63
2.2.4	Preparation of reagents for amplification of cDNA library	63
2.2.4.1	cDNA library	63
2.2.4.2	Bacterial host strain	64
2.2.4.3	20% (w/v) maltose	64
2.2.4.4	LB agar	64
2.2.4.5	1M MgSO <sub>4</sub>	65
2.2.4.6	LB/ MgSO <sub>4</sub> /maltose broth	65
2.2.4.7	LB/MgSO <sub>4</sub> soft top agarose	65
2.2.4.8	LB/ MgSO <sub>4</sub> agar	65
2.2.4.9	2% (w/v) gelatine	66
2.2.4.10	1X Lambda dilution buffer	66
2.2.5	Preparation of reagents for immunoscreening of cDNA library	66
2.2.5.1	Isopropyl-beta-D-thiogalactopyranoside (IPTG)	66
2.2.5.2	Nitrocellulose membrane filter (NCP)	66
2.2.5.3	Tris buffered saline (TBS)	66
2.2.5.4	TBS-Tween 20 (TBS-T)	67

2.2.5.5	Blocking solution	67
2.2.5.6	Primary antibody	67
2.2.5.7	Secondary antibody	67
2.2.5.8	Enhanced chemiluminescent (ECL) substrate	67
2.2.5.9	Developer	68
2.2.5.10	Fixer	68
2.2.5.11	Film	68
2.2.6	Preparation of reagents for cloning of recombinant plasmid	68
2.2.6.1	Magnesium chloride	68
2.2.6.2	Calcium chloride	68
2.2.6.3	Kanamycin solution	69
2.2.6.4	Kanamycin agar plate	69
2.2.7	Preparation of reagents for expression of recombinant protein	69
2.2.7.1	Terrific broth (TB)	69
2.2.7.2	Salt solution	69
2.2.7.3	Chloramphenicol stock solution	70
2.2.7.4	Kanamycin solution	70
2.2.7.5	1 M L-rhamnose	70
2.2.8	Preparation of reagents for protein extraction	70
2.2.8.1	<i>DNase 1</i>	70
2.2.8.2	Protease inhibitors, lysozyme	70
2.2.9	Preparation of reagents for native purification of His-tagged protein	71
2.2.9.1	Lysis Buffer	71
2.2.9.2	Washing buffer A, 20 mM imidazole	71
2.2.9.3	Washing buffer B, 30 mM imidazole	71
2.2.9.4	Washing buffer C, 40 mM imidazole	71
2.2.9.5	Elution buffer, 250 mM imidazole	72
2.2.10	Preparation of reagents for native purification of GST-tagged protein	72
2.2.10.1	1X GST Bind/Wash buffer	72
2.2.10.2	10X GST Elution buffer	72

2.2.10.3	Protein storage buffer	72
2.2.11	Preparation of reagents for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)	73
2.2.11.1	Resolving gel buffer	73
2.2.11.2	Stacking gel buffer	73
2.2.11.3	5X sample buffer	73
2.2.11.4	Running buffer	74
2.2.11.5	Ammonium persulfate	74
2.2.11.6	Staining solution	74
2.2.11.7	Destaining solution	74
2.2.12	Preparation of reagents for western blot	75
2.2.12.1	Transfer buffer	75
2.2.12.2	Washing and blocking solution	75
2.2.12.3	Primary and secondary antibodies	75
2.2.12.4	ECL substrate, fixer, developer and film	75
2.2.13	Preparation of reagents for lateral flow dipstick dot test	75
2.2.13.1	Membrane card, absorbent pad and micropipette well	75
2.2.13.2	Colloidal gold conjugate GST	76
2.2.13.3	Colloidal gold conjugate IgG4	76
2.2.13.4	Blocking solution	76
2.2.13.5	Chase buffer	76
2.2.13.6	Primary antibody	77
2.3	Methodology	77
2.3.1	Development of <i>in-house</i> IgG-, IgG4-, and IgE-ELISAs	77
2.3.1.1	Serum samples	77
2.3.1.2	Extraction of <i>S. stercoralis</i> crude antigen	78
2.3.1.3	Development of <i>in-house</i> ELISA	79
a)	Optimization of various parameters of ELISA	79
b)	ELISA procedure	80
c)	Determination of ELISA cut-off value (COV)	81
2.3.1.4	Screening and serum categorization	81
2.3.1.5	Commercial IgG ELISA kit	83

2.3.1.6	Statistical analysis	83
2.3.2	Serum pre-adsorption	84
2.3.2.1	Preparation of whole cell pellet of <i>E.coli</i> XL1-Blue	84
2.3.2.2	Preparation of cell lysate of <i>E.coli</i> XL1-Blue	85
2.3.2.3	Preparation of beads coated with <i>E.coli</i> lysate	85
2.3.2.4	Process of serum pre-adsorption	86
2.3.3	Immunoscreening of <i>S.stercoralis</i> cDNA library	87
2.3.3.1	Preparation of bacterial cell dilution	87
2.3.3.2	Phage library dilution	88
2.3.3.3	Titration and amplification of the original cDNA library	88
2.3.3.4	Primary immunoscreening of <i>Strongyloides</i> cDNA library	89
2.3.3.5	Signal generation detection	90
2.3.3.6	Isolation of reactive clone	91
2.3.3.7	Secondary immunoscreening of <i>Strongyloides</i> cDNA library	92
2.3.3.8	Tertiary immunoscreening of <i>Strongyloides</i> cDNA library	92
2.3.4	Post-immunoscreening analysis	93
2.3.4.1	<i>In-vivo</i> excision	93
2.3.4.2	Plasmid extraction	94
2.3.4.3	Determination of purity and concentration of the extracted plasmid	95
2.3.4.4	Sequencing analysis	95
2.3.5	Cloning of recombinant plasmids of potential cDNA inserts	96
2.3.5.1	Analysis of codon usage bias to <i>E.coli</i>	96
2.3.5.2	Preparation of competent <i>E.coli</i> cells	97
2.3.5.3	Cell transformation into <i>E.coli</i> TOP10 cloning host	97
2.3.5.4	Cell transformation into <i>E.coli</i> expression host	98
2.3.5.5	Long term storage of recombinant plasmid	98

2.3.6	Expression and purification of the recombinant proteins	99
2.3.6.1	Small scale protein expression	99
2.3.6.2	Large scale protein expression	100
2.3.6.3	Cell breakage	100
2.3.6.4	Purification of the His-tagged recombinant protein	101
2.3.6.5	Purification of the GST-tagged recombinant protein	101
2.3.7	Protein analysis by SDS-PAGE gel	102
2.3.8	Recombinant protein concentration and buffer exchange	103
2.3.9	Protein verification by western blot analysis	104
2.3.9.1	Protein transfer and membrane blocking	104
2.3.9.2	Detection of the recombinant protein	105
2.3.10	Proteolytic cleavage of GST tag from GST-tagged recombinant protein	106
2.3.11	Protein identity validation by MALDI-TOF/TOF	107
2.3.12	Evaluation of the antigenicity of the recombinant proteins by western blot analysis	109
2.3.13	Development of lateral flow dipstick dot test	110
2.3.13.1	Preparation of the dipstick for the GST-tagged recombinant protein	110
2.3.13.2	Preparation of the dipstick for the His-tagged recombinant protein	110
2.3.13.3	Procedure for the lateral flow dipstick test for the GST-tagged recombinant protein	111
2.3.13.1	Procedure for the lateral flow dipstick test for the His-tagged recombinant protein	112

## **CHAPTER THREE: RESULTS**

3.1	Development of <i>in-house</i> ELISA	114
3.1.1	Optimization of various parameters of ELISA	114
3.1.2	Determination of cut-off value	114
3.1.3	Screening and serum categorization	119

3.1.4	Statistical analysis	122
3.2	Serum pre-adsorption	125
3.3	Immunoscreening of <i>Strongyloides</i> cDNA library	127
3.3.1	Titration and amplification of the original cDNA library	127
3.3.2	Optimization of phage dilution	129
3.3.3	Optimization of conjugate dilution	131
3.4	Identification of reactive clones specific to IgG probe	133
3.4.1	Primary and secondary immunoscreening	133
3.4.2	Tertiary immunoscreening	133
3.4.3	Post-immunoscreening analysis	136
	3.4.3.1 Determination of purity and concentration of the extracted plasmid	136
	3.4.3.2 Sequencing analysis	136
3.5	Identification of reactive clones specific to the IgG4 probe	138
3.5.1	Primary and secondary immunoscreening	138
3.5.2	Tertiary immunoscreening	138
3.5.3	Post-immunoscreening analysis	141
	3.5.3.1 Determination of purity and concentration of the extracted plasmid	141
	3.5.3.2 Sequencing analysis	141
3.6	Cloning of Ss3a recombinant plasmid identified by IgG-phage immunoblot	143
3.6.1	Analysis of codon usage bias to <i>E.coli</i>	143
3.6.2	Recombinant protein rSs3a (IgG-detected clone)	148
3.7	Cloning of Ss1a recombinant plasmid identified by IgG4-phage immunoblot	153
3.7.1	Analysis of codon usage bias to <i>E.coli</i>	153
3.7.2	Recombinant protein rSs1a (IgG4-detected clone)	158
3.8	Expression and purification of rSs3a protein	161
3.8.1	Solubility test in small scale expression	161
3.8.2	Purification of rSs3a-His fusion protein	164
3.8.3	Purification of rSs3a-GST fusion protein	164
3.8.4	Protein verification of rSs3a by western blot analysis	167

3.8.5	Cleavage of GST tag from rSs3a protein	170
3.8.6	Protein identification of rSs3a by MALDI-TOF/TOF	172
3.8.7	Evaluation of diagnostic sensitivity and specificity of rSs3a by western blot analysis	177
3.9	Expression and purification of rSs1a protein	184
3.9.1	Solubility test in small scale expression	184
3.9.2	Purification of rSs1a protein	184
3.9.3	Protein verification of rSs1a by western blot analysis	186
3.9.4	Protein identification of rSs1a by MALDI-TOF/TOF	188
3.9.5	Evaluation of diagnostic sensitivity and specificity of rSs1a by western blot analysis	192
3.10	Development of a lateral flow dipstick test utilizing rSs3a protein	196
3.11	Development of a lateral flow dipstick test utilizing rSs1a protein	198
<b>CHAPTER FOUR: DISCUSSION</b>		203
<b>Limitations of the current study</b>		221
<b>Summary and conclusion</b>		224
<b>REFERENCES</b>		226
<b>APPENDICES</b>		246
-	Appendix 1 : Patent filed	246
-	Appendix 2a : Publication 1	249
-	Appendix 2b : Publication 2	250
-	Appendix 3a : Blast result of nucleotide sequence of Ss3a gene	251
-	Appendix 3b : Blast result of nucleotide sequence of Ss1a gene	253
<b>List of publications</b>		255

## LIST OF TABLES

	Page
Table 3.1a The results of the optimization assays for the <i>in-house</i> IgG-ELISA.	115
Table 3.1b The results of the optimization assays for the <i>in-house</i> IgG4-ELISA.	116
Table 3.1c The results of the optimization assays for the <i>in-house</i> IgE-ELISA.	117
Table 3.2 The results of the optimized parameters of <i>in-house</i> IgG, IgG4 and IgE-ELISAs and the COV for each test.	118
Table 3.3 List of serum samples used in this study.	118
Table 3.4 Detection of parasite-specific IgG, IgG4 and IgE responses against <i>S. stercoralis</i> measured by <i>in-house</i> and commercial IgG ELISA kit.	121
Table 3.5 Categorization of serum samples for use in the subsequent immunoscreening experiments.	121
Table 3.6 Evaluation of the diagnostic sensitivity and specificity of selected cDNA clones identified from IgG-immunoscreening.	134
Table 3.7 The results of sequencing analysis of the other 4 potential cDNA clones obtained from IgG-phage immunoblot.	137
Table 3.8 Evaluation of the diagnostic sensitivity and specificity of selected cDNA clones identified from IgG4-tertiary immunoscreening.	139
Table 3.9 The results of sequencing analysis of the other 6 potential cDNA clones obtained from IgG4-phage immunoblot.	142
Table 3.10 The summarized results of the evaluation of the diagnostic sensitivity and specificity of GST-rSs3a protein by western blot.	181
Table 3.11 The summarized results of the evaluation of the diagnostic sensitivity and specificity of rSs1a protein by western blot.	195
Table 3.12 Summary of the preliminary evaluation of the diagnostic sensitivity and specificity of the GST-rSs3a- and rSs1a-lateral flow dipstick dot tests.	200
Table 3.13 List of serum samples used for the evaluation of the diagnostic sensitivity of GST-rSs3a and rSs1a protein by western blot and lateral flow dipstick dot test.	202

## LIST OF FIGURES

	Page
Figure 1.1	The morphology of a) parasitic female, b) free-living male, and c) free-living female of <i>S. stercoralis</i> . 7
Figure 1.2	The life cycle of <i>S. stercoralis</i> . 10
Figure 1.3	Worldwide prevalence of strongyloidiasis. 16
Figure 1.4	The mechanism of innate immunity towards <i>S. stercoralis</i> larval killing studied in mice. 29
Figure 1.5	The adaptive immune response to <i>S. stercoralis</i> in mice. 30
Figure 2.1	The flowchart of the experiments in this study. 57
Figure 3.1	The results of one-way ANOVA to study the differences in <i>S. stercoralis</i> specific antibody titre measured by the <i>in-house</i> IgG, IgG4 and IgE ELISAs and commercial IgG ELISA. 123
Figure 3.2	Correlation studies between levels of (a) specific IgG ( <i>in-house</i> ) and IgG4, (b) IgG4 and IgG (IVD), (c) IgG ( <i>in-house</i> ) and IgG (IVD) antibodies to <i>S. stercoralis</i> in positive serum samples of patients with strongyloidiasis. 124
Figure 3.3	OD readings of pooled serum samples before and after pre-adsorption process determined by ELISA. 126
Figure 3.4 (a-f)	The images of plaques on agar plates at different phage dilutions. 128
Figure 3.5	Primary, secondary and tertiary immunoscreening results of <i>S. stercoralis</i> cDNA library probed with IgG and IgG4 antibodies. 130
Figure 3.6	The results of optimization studies of secondary antibody for IgG and IgG4 antibody conjugated to HRP. 132
Figure 3.7	Images of tertiary immunoscreening to test the diagnostic sensitivity and specificity of clone Ss3a using individual positive and negative pre-adsorbed serum samples probed with IgG conjugate. 135
Figure 3.8	Images of tertiary immunoscreening to test the diagnostic sensitivity and specificity of clone Ss1a using individual positive and negative pre-adsorbed serum samples probed with IgG4 conjugate. 140
Figure 3.9	The alignment of the non codon-optimized (NCD) and 145

	codon-optimized (CD) sequences of clone Ss3a.	
Figure 3.10	Analysis of nucleotide sequence of gene Ss3a before (left) and after (right) codon optimization.	147
Figure 3.11	Map of pET28a expression vector showing the location of Ss3a gene embedded in the vector sequence.	149
Figure 3.12	The predicted amino acid sequence of the Ss3apET28a construct showing the in-frame translation of Ss3a gene with histidine tag.	150
Figure 3.13	Map of pET42a expression vector showing the location of Ss3a gene embedded in the vector sequence.	151
Figure 3.14	The predicted amino acid sequence of the Ss3apET42a construct showing the in-frame translation of Ss3a gene with GST tag and Factor Xa coding sequence.	152
Figure 3.15	The alignment of the non codon-optimized (NCD) and codon-optimized (CD) sequences of clone SsIa.	155
Figure 3.16	Analysis of nucleotide sequence of gene SsIa before (left) and after (right) codon optimization.	157
Figure 3.17	Map of the pET28b expression vector showing the location of the SsIa gene embedded in the vector sequence.	159
Figure 3.18	The predicted amino acid sequence of SsIapET28b construct showing the in-frame translation of the SsIa gene with Trx and histidine tag coding sequence.	160
Figure 3.19	SDS-PAGE analysis of soluble and insoluble fractions of His-rSs3a protein expressed in <i>E.coli</i> BL21(DE3) host cell.	162
Figure 3.20	SDS-PAGE analysis of soluble and insoluble fractions of GST-rSs3a protein expressed in different <i>E.coli</i> host cells.	163
Figure 3.21	SDS-PAGE analysis of native purification of His-rSs3a protein.	165
Figure 3.22	SDS-PAGE analysis of native purification of GST-rSs3a protein.	166
Figure 3.23	Western blot analysis of soluble and insoluble His-rSs3a protein for the detection of His-tagged recombinant protein.	168
Figure 3.24	Western blot analysis of pooled fraction of rSs3a protein for detection of GST-tagged protein.	169

Figure 3.25	SDS-PAGE analysis of GST cleavage from the complex of rSs3a protein at two incubation periods.	171
Figure 3.26	Protein summary report for His-rSs3a protein.	173
Figure 3.27	Peptide summary report for His- rSs3a protein.	174
Figure 3.28	Protein summary report for GST-rSs3a protein.	175
Figure 3.29	Peptide summary report for GST- rSs3a protein.	176
Figure 3.30	Representative images of optimization of GST-rSs3a IgG-western blot at different primary and conjugate dilutions.	179
Figure 3.31	Representative images of optimization of GST-rSs3a IgG4-western blot at different primary and conjugate dilutions.	180
Figure 3.32	The IgG-western blot of GST-rSs3a protein tested on individual positive and individual negative serum samples.	182
Figure 3.33	The IgG4-western blot of GST-rSs3a protein tested on individual positive and individual negative serum samples.	183
Figure 3.34	SDS-PAGE analyses of a) soluble and insoluble fraction of rSs1a recombinant and b) native purification of rSs1a.	185
Figure 3.35	Western blot analysis of pooled rSs1a protein incubated with anti-histidine-HRP for detection of His-tagged protein.	187
Figure 3.36	Protein summary report for rSs1a protein when analyzed against with SwissProt database.	189
Figure 3.37	Protein summary report for rSs1a protein when analyzed against InformmDB.	190
Figure 3.38	Peptide summary report for rSs1a protein when analyzed against with SwissProt database.	191
Figure 3.39	Peptide summary report for rSs1a protein when analyzed against InformmDB.	192
Figure 3.40	Representative images of optimization of rSs1a IgG4-western blot at different primary and conjugate dilutions.	194
Figure 3.41	Images of the rSs3a-lateral flow dipstick dot test tested on individual positive and negative serum samples.	197
Figure 3.42	Images of the rSs1a-lateral flow dipstick dot test tested on individual positive and negative serum samples.	199

## LIST OF ABBREVIATIONS

ABTS	2,2'-Azino-d-[3-ethylbenthiazoline sulfonate]
APS	ammonium persulfate
Au-GST	colloidal gold conjugate GST
Au-IgG4	colloidal gold conjugate IgG4
BLAST	Basic Local Alignment Search Tool
bp	base pair
BSA	bovine serum albumin
CAI	codon adaptation index
cDNA	complementary DNA
COV	cut-off value
DMSO	dimethyl sulfoxide
DNA	deoxyribonucleic acid
<i>E.coli</i>	<i>Escherichia coli</i>
EDTA	ethylenediaminetetraacetic acid
ELISA	enzyme-linked immunosorbent assay
GST	glutathione s-transferase
His	histidine
HRP	horse-radish peroxidase
HTLV-1	Human T-cell lymphotropic virus
i.e.	id est (that is)
IFAT	immunofluorescence antibody test
INFORMM	Institute for Research in Molecular Medicine
IPTG	isopropyl-beta-D-thiogalactopyranoside
Kb	kilo base pair
kDa	kilo Dalton
LIPS	luciferase immunoprecipitation system
MALDI-TOF/TOF	matrix-assisted laser desorption/ionization-time of flight/time of flight
MS	mass spectrometry
MW	molecular weight
NC	nitrocellulose membrane
Ni-NTA	nickel-nitrilotriacetic acid
OD	optical density
ORF	open reading frame
pI	isoelectric point
PBS	phosphate buffered saline
PCR	polymerase chain reaction
pfu	plaque forming unit
RC DC <sup>TM</sup>	reducing agent detergent compatible
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel
STH	soil-transmitted helminths
TB	terrific broth
TBS	tris buffered saline
TEMED	tetramethylethylenediamine
UV	ultra violet
X-gal	5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside

**SERODIAGNOSIS UNTUK STRONGYLOIDIASIS:  
PENGENALPASTIAN KLOK cDNA, PENGHASILAN ANTIGEN  
REKOMBINAN DAN PEMBANGUNAN IMUNOASAI**

**ABSTRAK**

Strongyloidiasis merupakan penyakit parasit manusia yang disebabkan oleh cacing *Strongyloides stercoralis*. Jangkitan daripada cacing ini akan menyebabkan jangkitan jangka panjang dalam manusia, atau boleh disebarluaskan ke organ-organ lain, terutama bagi individu dengan sistem imun terkompromi, yang biasanya mengakibatkan kematian. Majoriti pesakit adalah tidak bersimptom, atau mengalami masalah gastrousus tak-spesifik, namun masih tiada kaedah ‘gold standard’ untuk mengesan jangkitan tersebut. Diagnosis definitif biasanya dilakukan melalui kombinasi tanda dan simptom klinikal, pengesanan mikroskopik, dan ujian serologi. Sehingga kini, ujian komersil yang sedia ada adalah berasaskan ekstrak asli antigen parasit, tetapi ujian tersebut mempunyai banyak kelemahan; contohnya masalah reaktiviti silang dengan jangkitan cacing yang lain. Ujian berasaskan antigen rekombinan merupakan alternatif yang sesuai bagi meningkatkan spesifisiti diagnostik dan keseragaman kualiti ujian, oleh itu, kajian ini dijalankan untuk mencapai matlamat ini. Peringkat awal kajian ini melibatkan pengujian sampel serum dengan *in-house* IgG-, IgG4- dan IgE-ELISA disamping kit komersial IgG-ELISA. Hasil keputusan mendapati bahawa asai IgG-ELISA menunjukkan sensitiviti yang tertinggi melalui kedua-dua asai *in-house* dan komersial (84.6%, n=26), manakala IgG4-ELISA menunjukkan spesifisiti yang tertinggi iaitu sebanyak 92.7% (n=55). Sampel serum dikategorikan mengikut kumpulan berdasarkan hasil keputusan IgG dan IgG4 untuk digunakan dalam eksperimen imunosaringan yang seterusnya.

Imunosaringan pertama perpustakaan faj cDNA *S. stercoralis* menghasilkan pemilihan sebanyak 20 cDNA klon bagi setiap faj imunoblot IgG- dan IgG4-. Klon-klon ini kemudiannya digunakan dalam imunosaringan kedua dan ketiga yang menggunakan sampel serum terjerap individu. Akhirnya, dua klon cDNA, iaitu Ss3a and SsIa, telah dipilih sebagai mempunyai nilai diagnostik yang berpotensi tinggi. Sisipan DNA bagi Ss3a adalah sangat serupa dengan protein hipotetikal *S. stercoralis*, manakala sisipan DNA bagi SsIa adalah sama dengan protein ikatan immunoglobulin *S. ratti*. Gen Ss3a telah diekspres secara rekombinan sebagai protein gabungan-GST di dalam vektor pET42a dan ia disahkan melalui analisis MALDI TOF/TOF. Nilai diagnostik bagi protein rekombinan rSs3a ditentukan melalui analisis western blot dengan menggunakan sampel serum individu. Seterusnya, ujian dipstik aliran sisi (1 jam) telah dihasilkan dengan sensitiviti dan spesifisiti sebanyak 100% (n=10) and 100% (n=10). Sementara itu, gen SsIa telah digabungkan dengan dua label protein dalam vektor pET28b dan diekspreskan sebagai protein gabungan-His, dan ia disahkan melalui analisis western blot dan MALDI-TOF/TOF. Kemudiannya, rSs1a telah dibangunkan kepada ujian pantas aliran sisi (15 minit), memberikan kadar sensitiviti sebanyak 90% (n=30) dan kadar spesifisiti sebanyak 98% (n=46). Kajian ini telah berjaya menemukan dua penanda jangkitan dan menghasilkan dua protein rekombinan dengan nilai diagnostik yang berpotensi. Bukti konsep penggunaan kedua-dua protein tersebut dalam ujian dipstik aliran sisi bagi serodiagnosis penyakit strongyloidiasis telah ditunjukkan, dengan kombinasi kedua-duanya mungkin sesuai digunakan sebagai ujian pantas untuk pengesan penyakit strongyloidiasis pada manusia.

**SERODIAGNOSIS OF STRONGYLOIDIASIS:  
IDENTIFICATION OF cDNA CLONES, PRODUCTION OF  
RECOMBINANT ANTIGENS AND IMMUNOASSAY DEVELOPMENT**

**ABSTRACT**

Strongyloidiasis is a human parasitic disease caused by the nematode *Strongyloides stercoralis*. Infection by this parasite can cause long-term infection in humans or can disseminate to other organs, especially in individuals with immunosuppression, which commonly results in fatal outcomes. The majority of patients are asymptomatic or present with non-specific gastrointestinal complaints, and there is no gold standard method to rule out the infection. Definitive diagnosis is usually made by a combination of clinical signs and symptoms, microscopic identification, and serology test. To date, the available commercial tests are based on native parasite antigen extract, but such tests have problems of cross-reactivity with other helminthic infections. A recombinant antigen-based test is a good alternative for improved diagnostic specificity and standardized test quality, thus, the present study was conducted to achieve this goal. The initial stage of the study involved testing serum samples with the *in-house* IgG-, IgG4- and IgE-ELISAs in addition to a commercial IgG-ELISA kit. The results showed that the IgG-ELISA assay demonstrated the highest sensitivity using either *in-house* or commercial assays (84.6%, n=26), whereas the IgG4-ELISA displayed the highest specificity of 92.7% (n=55). The serum samples were categorized into different groups based on the IgG and IgG4 results for use in the subsequent immunoscreening experiments. Primary immunoscreening of the *S. stercoralis* phage cDNA library resulted in the selection

of 20 cDNA clones from each IgG- and IgG4-phage immunoblot. These clones were subjected to secondary and tertiary immunoscreenings using individual pre-adsorbed serum samples. Finally, two cDNA clones namely Ss3a and SsIa were selected as having high potential diagnostic value. The Ss3a DNA insert was highly similar to a *S. stercoralis* hypothetical protein, while the SsIa DNA insert was identical to an immunoglobulin-binding protein of *S. ratti*. The Ss3a gene was recombinantly expressed as a GST-fusion protein in the pET42a vector and validated by MALDI TOF/TOF analysis. The diagnostic value of rSs3a protein was determined by western blot analysis using individual serum samples. Subsequently, a one-hour lateral flow dipstick test was produced with diagnostic sensitivity and specificity of 100%, respectively. Meanwhile, the SsIa gene was fused to a dual protein tag in the pET28b vector and expressed as a His-fusion protein and verified by western blot analysis and MALDI-TOF TOF. The rSs1a was then developed into a rapid (15 min) lateral flow dipstick test, which gave a sensitivity rate of 90% (n=30) and a specificity rate of 98% (n=46). This study has successfully discovered two infection markers and produced two new recombinant proteins of potential diagnostic value. Proof-of-concept of their usefulness in a lateral flow dipstick test for serodiagnosis of strongyloidiasis was also demonstrated, and in combination may serve as a good rapid test for of human strongyloidiasis.

# **CHAPTER ONE**

## **INTRODUCTION**

### **1.1 Strongyloidiasis: The overview**

Strongyloidiasis is a soil-transmitted helminthiasis capable of causing long-term infection as well as fatal consequences in humans. This disease is caused by two species of soil-transmitted helminths (STH) of the genus *Strongyloides*, namely, *Strongyloides stercoralis* and *S. fuelleborni*, with the former being the most prevalent species infecting humans. It is widely prevalent in populations living in tropical and sub-tropical climates, affecting approximately 100-370 million people worldwide (Bisoffi *et al.*, 2013).

The World Health Organization (WHO) has listed 17 diseases as neglected tropical diseases (NTDs). Seven of them are parasitic diseases, namely, cysticercosis, dracunculiasis, echinococcosis, foodborne trematodiases, lymphatic filariasis, onchocerciasis, schistosomiasis, and soil-transmitted helminthiases ([http://www.who.int/neglected\\_diseases/diseases/en/](http://www.who.int/neglected_diseases/diseases/en/)). These diseases were grouped as NTDs because they have been largely wiped out in the more developed parts of the world and persist only in the poorest, most marginalized communities and conflict areas; where they cause tremendous suffering due to their disfiguring, debilitating, and sometimes fatal impact (<http://www.cdc.gov/globalhealth/ntd/>).

Among the STH, attention has historically been focused on four species, namely, *Ascaris lumbricoides*, *Trichuris trichiura*, and hookworms (*Ancylostoma duodenale* and *Necator americanus*) (Krolewiecki *et al.*, 2013). Infection by *S. stercoralis* has received less attention and often overlooked because of the major challenges presented in measuring the infection and the complex diagnostic methods.

Therefore, strongyloidiasis is mostly known as “the most neglected of the neglected tropical diseases” (Olsen *et al.*, 2009).

Although the need for research to improve the diagnosis of strongyloidiasis had been highlighted over three decades ago, there is still no definitive or “gold standard” method to rule out the infection. This is the reason for the undetected persistence of the parasite inside the human body over decades, with the current record of chronic infection for 75 years (Prendki *et al.*, 2011).

The clinical manifestations of the disease ranges from asymptomatic light infection to chronic symptomatic infection, or it may progress to life-threatening dissemination of larvae to all internal organs among individuals with compromised immune system (Olsen *et al.*, 2009). It was reported that strongyloidiasis was accountable for a mortality rate of about 60-85% amongst immunocompromised patients (Ericsson *et al.*, 2001) and contributed to 16.7% of the mortality rate for patients requiring hospitalization (Iriemenam *et al.*, 2010).

Cases of patients infected with strongyloidiasis have recently increased due to the increasing numbers of transplant recipients and patients with altered immune status, malignancies and malnutrition. These complications are highly associated with the immunosuppression caused by corticosteroids and infection with human T lymphotropic virus type 1 (HTLV-1), the two most common risk factors for strongyloidiasis; however, the greatest risk is visiting an endemic area (Mirdha, 2010).

As strongyloidiasis contributes to serious outcomes in certain groups of populations, misdiagnosis and untreated infections could lead to fatality, prompting serious problems in the community. Therefore, understanding the nature, epidemiology, and immunological factors of *S. stercoralis* as well as the overall

aspect of strongyloidiasis may lead to better prevention, diagnosis, and treatment of the disease.

## **1.2 History of the discovery of *S. stercoralis***

*S. stercoralis* was first described back in July 1876 by Louis Normand, a military physician from France. He discovered a novel worm in the faeces of soldiers returning from World War II and the Cochin-China (Vietnam) war who were suffering from diarrhoea. The worm was then named *Anguillula stercoralis* by his colleague, Bavay, to reflect its shape (Latin: “anguillula” = “eel” and “stercus” = “dung”). Bavay was also the first to describe the free-living adults parasite he found *in vitro* (Grove, 1995).

Then, in 1878, Grassi and Parona from Italy reviewed the findings of this parasite and renamed it *Strongyloides intestinalis* (Greek: “Strongylos” = “round” and “Eidos” = “similar”). However, in 1881, the name of this parasite was once again changed by Perroncito, who called it *Pseudorhabditis stercoralis*, as he found and cultivated free-living adult worms from larvae identical to the *A. stercoralis*. Two years later, Leuckart realized that all of these worms were the same but from different phases in the life cycle of a single parasite. He then suggested the name “*Rhabdonema strongyloides*”. After several names had been suggested and changed, finally, in 1902, Stiles and Hassall pointed out that the correct name of this parasite should be *Strongyloides stercoralis*, and this name was accepted by the International Commission on Zoological Nomenclature in 1915 (Lindo and Lee, 2002).

The migratory route of this parasite inside the host was first studied by Fulleborn in 1914 (Cox, 2002). It was not until the 1930s, 50 years after its first

discovery that the full life cycle, pathology, and clinical features of *S. stercoralis* in humans were fully disclosed (Schär *et al.*, 2013).

### **1.3 The organism *S. stercoralis***

#### **1.3.1 Taxonomy**

The species *S. stercoralis* is classified under the genus *Strongyloides*, family of Strongyloididae, order Rhabditida, class Secernentea, and phylum Nematoda. In the United States, this genus is commonly known as threadworm, and it is called pinworm in the United Kingdom (Liu, 2012). There are more than 52 species of the genus *Strongyloides*; however, only two species are known to parasitize humans, namely *S. stercoralis* and *S. fuelleborni*, with the former the most pathogenic species in humans and causes majority of the infections. Other than humans, dogs and primates are also susceptible to infection with *S. stercoralis* (Bonne-Année *et al.*, 2011).

*S. fuelleborni* is a zoonosis that usually occurs in non-human primates, and the main source of infection is monkey faeces. There are two subspecies of *S. fuelleborni*, namely *S.f. fuelleborni* and *S.f. kellyi*, which are reported to cause infection in humans in Africa and Papua New Guinea respectively (Cox, 2002). According to King and Mascie-Taylor (2004), *S.f. kellyi* is responsible for 27% of *Strongyloides* infections amongst children, with 81% of them being under 12 months old. It caused a potentially fatal disease among children called ‘swollen belly syndrome’ (SBS). The high percentage of incidence among young children might be due to the habits of the mothers, who carry their children in string bags lined with dried banana leaves and/or cloth. These materials are changed infrequently, and eggs and free-living larvae have been found (Brooker and Bundy, 2009).

The difficulty in maintaining *S. stercoralis* in the respective host limits the investigation into this organism; therefore, *S. ratti* and *S. venezuelensis*, which naturally infect rodents, have been used to study the biology and immunology of *Strongyloides* infection (Bonne-Année *et al.*, 2011). Some limitations have been encountered with such studies, as the results generated with rodent parasites do not mimic the actual pathogenesis of the human pathogen *S. stercoralis*. They migrate throughout the body; therefore the recovery of the parasites is problematic, and study of the microenvironment of the host is nearly impossible (Bonne-Année *et al.*, 2011).

### 1.3.2 Morphology


*S. stercoralis* has two different life cycles, namely, the parasitic and the free-living life cycles. The morphology of the parasite in the former is different from in the latter. Figure 1.1 shows the difference in the morphology of adult *S. stercoralis* larvae between the two life cycles, i.e. parasitic female, free-living male and free-living female.

The parasitic female of *S. stercoralis* is approximately 2.0-2.8 mm in length, has an average diameter of 37 µm, and a blunt-ended tail. It is very slender and threadlike, giving rise to the common name, ‘threadworm’ (Lindo and Lee, 2001). As described by Grove (1995), the body of the female worm is attenuated anteriorly, and it contains a long cylindrical oesophagus (also called the pharynx). The oesophagus is followed by the intestine and is surrounded by a nerve ring. The vulva is located in the mid-ventral line in the posterior third of the body (Grove, 1995). Parasitic worms are parthenogenetic females; their reproductive organs develop after the male reproductive organs have disappeared. There is no parasitic male (Simon, 2009).

The length of the free-living adult female is shorter, ranging from 0.9-1.7 mm, but the diameter is about 85  $\mu\text{m}$ . It has a thin cuticle and is transparent, and the oesophagus is attached to the terminal mouth. The reproductive system is similar to that seen in the parasitic female except that each uterus contains numerous eggs (Grove, 1995). However, using a dissecting microscope, the free living adult female is easily seen in cultures, while the parasitic female is barely visible in stool samples, except in a very severe infection (Lindo and Lee, 2001). This is because the parasitic females lie embedded within the mucosal epithelium of the proximal small intestine where they deposit their eggs (Simon, 2009).

The free living male of *S. stercoralis* is approximately 1.0-1.2 mm long and 55  $\mu\text{m}$  in diameter and has a typical J shape with a sharply pointed tail (Lindo and Lee, 2001). The mouth, oesophagus, and intestine are similar to those seen in the free-living female. The reproductive system consists of a blindly ending testis at the anterior end, and it is attached to a poorly demarcated vas deferens and seminal vesicle (Lindo and Lee, 2001).

The eggs of parasitic and free-living females are morphologically similar, with a thin-shelled, ellipsoidal shape, and measure between 40 x 70  $\mu\text{m}$  in size (Grove, 1995). The eggs may be fully embryonated when laid or may have undergone several cell divisions (Lindo and Lee, 2001). The eggs hatch within the submucosa or during passage through the lumen of the intestine, liberating rhabditiform larvae, which are then excreted with the faeces (Nappi and Vass, 2002).



[http://rowdy.msudenver.edu/~churchcy/BIO3270/Images/Nematodes/Strongyloides\\_stercoralis.htm](http://rowdy.msudenver.edu/~churchcy/BIO3270/Images/Nematodes/Strongyloides_stercoralis.htm)

**Figure 1.1** The morphology of a) parasitic female, b) free-living male, and c) free-living female of *S. stercoralis*.

### 1.3.3 Life cycle

The life cycle of *S. stercoralis* is unique, with its alternation between free-living and parasitic cycles enabling the worms to live in the environment and in the human host. Additionally, this parasite has the potential for autoinfection and multiplication within the host, making it different from any other nematode. Two types of life cycles exist, that is, an external sexual cycle involving free-living worms in the environment and an internal asexual cycle involving parasitic worms in the host. Therefore, reproduction takes place at two different sites. Figure 1.2 depicts a summary of its life cycle.


Infection is initiated when a free-living third-stage infective larva (L3) penetrate the skin of the human host. There is then a period of larval migration within the host, during which the L3 larvae undergo rapid development from the free-living third-stage larvae to a post-penetration, host-adapted transformed stage called the L3<sup>+</sup> (Bonne-Année *et al.*, 2011; Brigandi *et al.*, 1998; Brigandi *et al.*, 1997). The L3<sup>+</sup> differs antigenically as well as physiologically from the L3 due to the different environments where the two forms of larvae reside, as reported by Maruyama *et al.* (2006) (Bonne-Année *et al.*, 2011). Females are the only adult worms to form the parasitic stages of *Strongyloides*, as the male disappears from the bowel soon after oviposition (Viney and Lok, 2007).

Inside the host, eggs are produced by the female worms parthenogenetically, that is, via asexual reproduction without the presence of the adult male worm (Brooker and Bundy, 2009). The female worms deposit their eggs in the mucosal epithelium of the small intestine. The eggs then hatch to become rhabditiform larvae or are passed in the stool, and so enter the free-living cycle, which is sometimes called the external parasitic, indirect, or sexual cycle. Thus, the presence of

rhabditiform in the stool sample is considered as diagnostic of strongyloidiasis, since the eggs are rarely found (Lindo and Lee, 2001)

Inside the host's gut, the rhabditiform L1 emerge from the eggs and moult twice to become infective L3 larvae while they are still in the intestinal lumen of the host. The infective filariform larvae then penetrate either the intestinal mucosa, causing internal autoinfection, or the skin of the perianal area, causing external autoinfection (<http://www.cdc.gov/parasites/strongyloides/biology.html>). This cycle continues, with the female adult larvae producing eggs parthenogenetically 25-30 days after initially penetrating the skin (Liu, 2012). The ability of autoinfection to initiate a new life cycle allows the persistence of the infection for decades.

In the free-living stage, the rhabditiform larvae undergo further development in the soil, moulting directly to become infective filariform larvae via the homogonic cycle (Nappi and Vass, 2002). Alternatively, when the environmental conditions are optimal, rhabditiform larvae develop into free-living male and female adult worms that mate and produce eggs; the eggs hatch to release L1 larvae, moult again to become L2, and then again to become the infective filariform L3 stage through the heterogonic cycle (Grove, 1995). The infective L3 stages produced by these two cycles are long lived, and they can persist in the environment until they encounter a suitable host, continuing the life cycle following skin penetration (Viney and Lok, 2007).



<http://www.cdc.gov/dpdx/strongyloidiasis/index.html>

**Figure 1.2** The life cycle of *S. stercoralis*

### **1.3.3.1 Autoinfection**

Autoinfection is defined as the ability to replicate and multiply within the same host in the absence of external sources of infection (Gillespie and Pearson, 2001). In the *Strongyloides* genus, *S. felis* was found to have this trait as well as *S. stercoralis* (Speare and Durrheim, 2004). As mentioned previously, autoinfection may arise in one of two ways: i) the filariform larvae penetrate and lodge in the intestinal mucosa (internal autoinfection), or ii) the filariform larvae re-invade the bowel or perianal skin (external autoinfection) (Liu, 2012; Brooker and Bundy, 2009). The capability to establish a new cycle of repeated endogenous infection in the human host means the infection can persist for up to 75 years in immunocompetent individuals (Prendki *et al.*, 2011). In immunocompromised individuals, it can lead to possible multiplication causing a tremendous increase in the worm burden, which in turn, leads to hyperinfection or disseminated syndrome (Liu, 2012).

## **1.4 Epidemiology**

Strongyloidiasis is endemic worldwide; it can be found in countries with hot and humid climates but predominantly in resource-poor countries with inadequate sanitary conditions. The current prevalence of strongyloidiasis is estimated to be around 100-300 million cases (Taylor *et al.*, 2014). This prevalence varies substantially between countries and continents due to ecological, socio-cultural, and economic factors, in addition to the type of diagnostic method and the number of studies undertaken. A review study conducted by Schär *et al.* (2013) reported a countrywide prevalence of strongyloidiasis based on three different subsets: community-based studies, hospital-based studies, and studies on refugees and immigrants.

Community-based studies have revealed that Brazil and Thailand are endemic countries for strongyloidiasis, and these two countries possess reliable and consistent data on the infection, with the proportion of the infection reported as being 13% and 23.7% respectively (Schär *et al.*, 2013). One of the biggest community-based studies was conducted in Africa, and involved screening 20,250 individuals across 216 villages; the study revealed an infection rate of 11.6% among the community (Schär *et al.*, 2013; Yelifari *et al.*, 2005). Meanwhile in Japan, strongyloidiasis was found in older persons, with sustained infection, probably due to auto-infection, contributing to an overall infection rate of 16.4% in an endemic area of Okinawa prefecture (Arakaki *et al.*, 1992). In a study conducted by Steinmann *et al.* (2007), the reported prevalence of strongyloidiasis in China was 11.7%, in which the endemic areas were found to be mostly farming communities. Based on the results of five prevalence studies, the reported prevalence of strongyloidiasis in Australia was found to be in the range of 0% to 60%, with screening taking place among the aboriginal communities in northern Australia (Johnston *et al.*, 2005).

A hospital-based study analysing 37,621 laboratory specimens over a period of two years in the Campinas City region in Brazil demonstrated an overall prevalence rate of 10.8% (Rossi *et al.*, 1992), while a prevalence rate of 11.2% in India was obtained from nine hospital-based prevalence studies, five of which focused on the screening of HIV/AIDS patients (Schär *et al.*, 2013).

In the US, 347 deaths related to strongyloidiasis were reported from 1991 to 2006; this figure is equivalent to 14-29 deaths per year (Croker *et al.*, 2010). The prevalence studies in Americas were well covered; two thirds of the epidemiologic studies in America focused mainly on refugees and immigrants. Similarly, seroprevalence studies in European countries focused on refugees, immigrants, and

travellers . In the United Kingdom, it is believed that *S. stercoralis* infection might have persisted over a long period, since many of the infections were identified among World War II veterans who had not left the country in the 60 years following their return from deployment in Southeast Asia (Schär *et al.*, 2013). The reported prevalence in the UK was 12% (Gill *et al.*, 2004). In Canada, a strongyloidiasis prevalence rate of 11.8% was reported among Vietnamese refugees, and 76.6% among Cambodian refugees (Gyorkos *et al.*, 1990). Screening of 5,518 female housekeepers from different Asian countries working in Saudi Arabia revealed an overall prevalence of 0.6%, of which 0.4% were Filipinos, 0.5% Indonesians, 1.5% Sri Lankans, 2.6% Indians and 3.4% Thais (Madani and Mahfouz, 1995).


South-East Asia (SEA) possesses climatic, ecological, and socio-economic conditions that favour the transmission of *S. stercoralis*. Yet, information on the occurrence of strongyloidiasis from these countries is relatively scarce. In a systematic literature review of all peer-reviewed research articles published over the last 25 years conducted by Schär *et al.* (2015), they reported that the prevalence of *S. stercoralis* in Thailand ranged from 0.1% to as high as 38.8% when the infection was screened for among the general population, i.e. villagers and school-children. Thailand had by far the most extensive studies on the prevalence of strongyloidiasis among any other SEA countries. Meanwhile, a cross-sectional study carried out by Khieu *et al.* (2014) in rural Cambodia revealed that strongyloidiasis is highly prevalent among the general Cambodian population, with a prevalence rate of 44.7%. It is likely that the examination of multiple stool samples, the range of diagnostic methods employed, and poor sanitary conditions are the main factors that contributed to the high prevalence rate reported in this area. Similar reasons were also likely to be the main cause of the high prevalence rate of strongyloidiasis (41%) reported in

Lao PDR (Vonghachack *et al.*, 2015). Seven screening studies conducted in Indonesia, covering the areas of Flores Island, Bali, and Irian Jaya Island, reported a prevalence rate lower than 1.0% to 1.6% (Schär *et al.*, 2015). This low reported prevalence is believed to be due to the use of not highly sensitive diagnostic method (i.e. Harada-Mori technique) and the limited presence of *S. stercoralis* larvae. Meanwhile, no *S. stercoralis* infection was found in a study conducted in Vietnam. However, since the prevalence of hookworm infection was reported to be 28.6%, it is believed that strongyloidiasis is probably also present in Vietnam (Hung *et al.*, 2005). No published report could be found on the prevalence rate of strongyloidiasis in Singapore, Brunei, Myanmar, and the Philippines (Schär *et al.*, 2015).

In Malaysia, the first review case of a patient with gastric strongyloidiasis was histologically documented by Shekhar *et al.* (1997). Kuze *et al.* (2010) published a paper on the discovery of the rhabditoid larvae of *Strongyloides* sp. and *S. fuelleborni* from the faeces of orang utans in Sabah. Studies on the prevalence of *S. stercoralis* infection in this country is very limited; only four studies were conducted from 1997 to 2013, two of which studied the minority community of Orang Asli in rural areas and the rest were hospital-based studies in Sarawak and Kelantan. Rahmah *et al.* (1997) reported a low prevalence (1.2%) of strongyloidiasis among the Orang Asli minority community in Kelantan. In the same minority community, Ahmad *et al.* (2013) found no *S. stercoralis* larvae in 54 coprologically analyzed stool samples; however, serological examination of the corresponding serum samples revealed a prevalence of 31.5%. In a hospital-based study among patients with gastrointestinal symptoms in an endemic area of STH Sarawak, Basuni *et al.* (2011) reported a prevalence of strongyloidiasis to be 39.0% using pentaplex-PCR. Investigation of *S. stercoralis* infection among cancer patients in a major hospital in

Kelantan using several detection methods by Zeuter *et al.* (2014) revealed a seroprevalence of 3.1% when measured by IgG4-ELISA, 0.5% by microscopy and 1.6% by real-time PCR.

Figure 1.3 shows the prevalence of strongyloidiasis worldwide. It is noted that the high prevalence rates of *Strongyloides* infection were noted in areas where rigorous diagnostic approaches were engaged in the studies, be it due to multiple diagnostic methods or the large numbers of samples examined. In contrast, the low prevalence reported in certain areas might be due solely to the low sensitivity of the diagnostic method employed. This suggests that the prevalence of strongyloidiasis worldwide might be underestimated, as research into prevalence is highly dependent on the factors mentioned above. Therefore, a more sensitive and specific diagnostic method is required for an accurate measurement of prevalence as well as mapping the endemicity of the infection.



**Figure 1.3** Worldwide prevalence of strongyloidiasis

Puthiyakunnon *et al.*, 2014

## **1.5 Transmission of the infection**

### **1.5.1 Horizontal transmission**

Humans are generally infected by *S. stercoralis* transcutaneously when the infectious filariform larvae in faecally contaminated soil enter the skin or mucous membranes during agricultural, recreational, or domestic activities (Ramanathan and Nutman, 2008). There are also cases of infection induced by the oral administration of water contaminated with filariform larvae (Keiser and Nutman, 2004) or the ingestion of contaminated food (Wirk and Wingard, 2009). Human-to-human transmission is uncommon; however, such transmission has been described among homosexual men (Simon, 2009). A group of cases were also reported in institutionalized individuals with mental retardation, suggesting that nosocomial transmission could possibly occur (Keiser and Nutman, 2004).

#### **1.5.1.1 Soil transmission**

Humans are prone to *S. stercoralis* infection when the person is exposed to contaminated soil harbouring infective filariform larvae. Thus, visiting an endemic area becomes the largest risk factor for acquiring *S. stercoralis* infection. Two cases of acute strongyloidiasis infection were reported in Italian tourists after visiting beaches in Koh Samui Island, Thailand (Angheben *et al.*, 2011). Meanwhile, bathing in the rivers and consuming non-drinking water has been shown to have a significant association with strongyloidiasis (Herrera *et al.*, 2005). Farmers and coal miners are the two occupations with the highest risk of getting the infection, while children are prone to this disease due to their behaviours, which favour the transmission of the soil-based helminths – dirty hands, mouth contact, and going bare foot when playing on contaminated ground (Liu, 2012).

### **1.5.1.2 Oral route of transmission**

The *Strongyloides* larvae have been found contaminating local vegetation, by which the infection can be transmitted orally to humans. Some people especially Kelantanese have the custom of eating raw vegetables and herbs, i.e. *daun kesum* (Vietnamese mint), *pegaga* (*Centella asiatica*), and water spinach (*Ipomoea aquatic*); these plants are collectively known as *ulam* (Zeehaida *et al.*, 2011). Most of these *ulam* grow in areas near the drains, a place that favours the growth of the parasite. Zeehaida *et al.* (2011) revealed the presence of live rhabditiform *S. stercoralis* larvae in the water samples used to wash these vegetables, highlighting the possibility of oral route transmission to the public, vegetables sellers and food handlers.

### **1.5.1.3 Person to person transmission**

The possibility of the transmission of larvae from one person to another via direct contact is low; hence, few reports are available. In 1982, Grove conducted a survey investigating the possible transmission of *S. stercoralis* from 24 men who had been infected with strongyloidiasis for many years to their spouse. The results showed that none of the wives were infected, suggesting that the risk of transmission is small. Indeed, no evidence of transmission was found in medical staff in charge of patients with disseminated strongyloidiasis (Sugiyama *et al.*, 2006; Maraha *et al.*, 2001). However, the risk of infection could still be present if safety precautions are not strictly followed. For instance, Czachor and Jonas (2000) reported a case of *S. stercoralis* infection in an 84-year old wife who had routinely provided personal care and attended to the secretions of her ill husband, who had hyperinfestation syndrome.

The wife presented with uncharacterized symptoms two weeks after her husband's death.

The likelihood of transmission among homosexuals is greater (Grove, 1982). A case was reported by Sorvillo *et al.* (1983) who identified the presence of *S. stercoralis* in the faeces of a homosexual patient and his contacts. Thus the risk of person-to-person transmission among homosexuals should not be ignored.

### **1.5.2 Vertical transmission**

The occurrence of vertical transmission of strongyloidiasis in humans is unknown. In a study conducted by Shoop *et al.* (2009), they examined the possibility of the vertical transmission of *S. stercoralis* in three female dogs at a different stages of the reproductive cycle (preconception, gestation, and postpartum) which were injected with *S. stercoralis* filariform larvae. None of the pups born to females infected before conception and during gestation harboured the larvae, thus showing that transmission through prenatal pathways does not occur. However, live filariform larvae of *S. stercoralis* were found in milk samples taken from lactating female dogs, suggesting that transmission of the parasite through transmammary route. The larvae are able to become dormant in the tissue, and this was found to be the key for transmammary transmission. The infective L3 presumably arrest their development and migration in the mammary glands, and then reactivate at lactation (Liu, 2012).

Recently, a single case of a pregnant woman who died due to strongyloidiasis has been reported by Buresch *et al.* (2015). The woman, who was at week 25 of gestation, was given a corticosteroid to resolve the acute abdominal pain and abnormal foetal heart tracing. Unfortunately, she developed septic shock, due to hyperinfection causing stillbirth to occur, and finally she succumbed to the disease.

## **1.6 Clinical manifestation of strongyloidiasis**

### **1.6.1 Acute**

The primary infection with *S. stercoralis* is initiated by penetration of the infective filariform larvae through the intact skin. This early stage of infection is usually asymptomatic, or it may manifest as mild larva currens, an allergic reaction due to migration of the filariform larvae (Mahmoud, 1996). The migration can progress as quickly as 10 cm/hr (Satoskar *et al.*, 2009). Slight haemorrhage, swelling, and itching are sometimes noted at the site of larva entry; these symptoms can occur almost immediately and can last for several weeks (Keiser and Nutman, 2004; Freedman, 1991).

After penetrating the skin, the infective filariform larvae enter the blood, and they are then transported to the lungs via the pulmonary circulation. At this time, patients usually suffer from symptoms that resemble Loeffler's syndrome, such as coughing, shortness of breath, wheezing, and transient pulmonary infiltrates (Mahmoud, 1996). Inside the lungs, the larvae penetrate the alveoli and migrate upwards to the tracheobronchial tree; they are then swallowed entering the gut, where they complete their maturation. These larvae will then moult to become adult female worms and lodge in the submucosal tissues inside the proximal small intestine (Simon, 2009). At this stage, abdominal symptoms and signs such as indigestion, cramping abdominal pain, and diarrhoea with malabsorption and weight loss, have been commonly observed (Mahmoud, 1996) about two weeks after infection, with the larvae detectable in the stool after three to four weeks (Keiser and Nutman, 2004). All of these may be misdiagnosed as being due to irritable bowel syndrome (Grove, 1995).

### **1.6.2 Chronic**

Unresolved acute infection can lead to the development of chronic infection, causing a variety of manifestations, most commonly infections to the skin and gastrointestinal system (Grove, 1995). Meanwhile, chronic infection, without prompt diagnosis and proper treatment can lead to severe complicated strongyloidiasis characterized by a wide range of complicated forms of disease, including gastrointestinal, pulmonary, and neurological complications and other presentations such as urinary tract infections and pelvic inflammation (Grove, 1995). The major target areas are the bowel, lungs, and central nervous system. Usually, this leads to presence of secondary bacterial infection, which increases the risk of mortality in patients not only due to the hyperinfection syndrome, but also due to the underlying condition which predisposes to dissemination (Grove, 1995).

Autoinfection is the main reason for the persistence of this organism in the host for decades. A more severe form of autoinfection is the hyperinfection syndrome (HS). The hallmark of HS is an increase in the number of larvae found in the stool and/or sputum along with a clinical manifestation that is confined to the usual migratory pathway of the parasite, i.e. the respiratory and gastrointestinal systems and the peritoneum (Liu, 2012). Patients with HS at the gastrointestinal sites usually suffer from clinical manifestations, such as cramping abdominal pain, watery diarrhoea, nausea, vomiting, gastrointestinal bleeding, and weight loss. Meanwhile, hyperinfection in the extraintestinal sites include coughing, wheezing, and pulmonary haemorrhaging with diffuse bilateral infiltrates seen on the chest x-rays (Liu, 2012).

The key factors contributing to HS are drug-induced or concurrent immunosuppressive conditions, such as solid tumours, corticosteroid use, HTLV-1

and HIV infection, or Hodgkin's lymphoma (Gillespie and Pearson, 2001). HS occurs in 1.5-2.5% of patients with strongyloidiasis, contributing to a 15% mortality rate among HS patients, which increases to 87% when there is dissemination (Marcos *et al.*, 2008; Vadlamudi *et al.*, 2006).

The uncontrolled HS may result in the dissemination and massive migration of the infective larvae outside the usual migration pattern to the other extraintestinal organs; this usually leads to a fatal outcome. The larvae are found in other organs, including the liver, the kidneys, and the central nervous system (Simon, 2009). During the migration, the larvae facilitate the translocation of intestinal bacteria, such as *Streptococcus bovis*, *Escherichia coli*, *Streptococcus fecalis*, *Klebsiella pneumonia*, or *Enterobacter sp.* to other locations of the body (Liu, 2012). These gut flora invade the host tissues either through the penetration of infective larvae from the bowel lumen or through the damaged intestinal epithelium causing concomitant secondary disease, such as septicaemia, meningitis, liver abscess, and pancreatitis (Mahmoud, 1996). Cases of disseminated strongyloidiasis have been reported to be associated with systemic erythematosus (SLE) (Setoyama *et al.*, 1997), nephrotic syndrome (Morimoto *et al.*, 2002), and malignant tumours (Genta *et al.*, 1989).

## **1.7 Strongyloidiasis in patients with associated problems**

### **1.7.1 Immunosuppressed patients**

Immunosuppressed patients are among the populations most at risk of developing the life-threatening clinical syndromes associated with strongyloidiasis, i.e. HS or dissemination (Marcos *et al.*, 2011). These patients include those with human T-cell lymphotropic virus type I (HTLV-I) infection, patients with hematologic malignancies, and patients who have received systemic corticosteroids or an

allogeneic hematopoietic stem cell transplantation (HSCT) (Marcos *et al.*, 2008). Indeed, leukaemia and lymphoma account for up to 90% of the cases of malignancy-associated severe strongyloidiasis (Schaffel *et al.*, 2001; Igra-Siegman *et al.*, 1981).

In the US, the overall frequency of infection amongst 322,593 cancer patients diagnosed between 1971 and 2003 was found to be 0.8 per 10,000 patients and to be 2.0 per 10,000 among patients with leukaemia (Safdar *et al.*, 2004). Meanwhile, in Malaysia, *S. stercoralis* infection was detected in 4.2% of cancer patients, thus highlighting the high association of strongyloidiasis among immunosuppressed cancer patients (Zueter *et al.*, 2014).

In general, immunosuppression develops one to three weeks after the administration of the immunosuppressant (Thackery, 2002), and signs and symptoms of strongyloidiasis are seen in immunosuppressed patients as early as 20 days and as late as several years after the onset of steroid therapy (Keiser and Nutman, 2004). In a high-dose corticosteroid treatment, it can take less than ten days to transform a previously clinically silent undetected infection into overwhelming dissemination (Genta, 1992). Patients of these cases mostly received glucocorticoids (one of the corticosteroids), which is the most widely used treatment and the most specifically associated with transforming chronic strongyloidiasis to hyperinfection (Keiser and Nutman, 2004).

The link between corticosteroid therapy and strongyloidiasis has been widely reviewed. According to Corrigan (1999), the corticosteroids have the effect of reducing the levels of circulating eosinophils by inhibiting their proliferation and increasing apoptosis, in addition to inducing cell death in immature lymphocytes (Marcos *et al.*, 2008). It was also been hypothesized that corticosteroids may directly affect the female worms, accelerating the transformation of rhabditiform to invasive

filariform larvae (Genta, 1992), or rejuvenating reproductively latent adult females (Keiser and Nutman, 2004; Mansfield *et al.*, 1996).

The use of other immunosuppressants other than corticosteroids has also been associated with a number of cases of hyperinfection, i.e. vinca alkaloids (Jamil and Hilton, 1992), cyclosporine (Palau and Pankey, 1997), azathioprine (Weller *et al.*, 1981), and VP16 (Tabacof *et al.*, 1991).

### **1.7.2 Association with solid organ transplantation**

More than one-half of cancer patients who had strongyloidiasis also had an underlying solid-organ malignancy (Safdar *et al.*, 2004). Post-transplantation tropical infection is a major risk in the organ recipient, which is frequently misdiagnosed by clinicians. It is thought that most *Strongyloides* infections in organ transplant recipients are caused by the reactivation of chronic infection after the initiation of immunosuppressive therapy or donor-derived infection.

The incidence of *Strongyloides* infection post-transplantation in organ recipients is increasing annually due to the increase in international travel and the rising number of transplant procedures taking place in tropical countries. The most frequent occurrence of *Strongyloides* infection was found in renal transplantation (Marcos *et al.*, 2008), with one of the earliest cases described in 1971 (Snydman *et al.*, 2009; Fagundes *et al.*, 1971). Other cases of strongyloidiasis have also been reported in recipients of intestinal transplant (Patel *et al.*, 2008), liver transplant (Rodriguez *et al.*, 2009), heart transplants (Ziad El Masry and O'Donnell, 2005) and lung transplants (Balagopal *et al.*, 2009). Two cases of symptomatic chronic strongyloidiasis in immunosuppressed children following treatment for solid organ malignancies were reported in Malaysia by Norsarwany *et al.* (2012).